Blood cancer is not one disease and it is not staged the way breast or lung cancer is. Leukemia, lymphoma and multiple myeloma each have their own staging or risk frameworks, and the same word “stage” can mean very different things depending on which family of disease a patient has. This page explains how hematologists in Delhi, Gurgaon and Noida actually decide stage and risk for the common blood cancers, what each stage means for treatment, and what families can expect when they walk into a tertiary cancer centre in the National Capital Region.
What Blood Cancer Staging Actually Means
Solid tumours are staged by size, lymph node spread and distant metastases, the familiar TNM system. Blood cancers do not form a single mass that can be measured with a ruler. Instead, hematopathologists group these cancers by where the abnormal cells live (bone marrow, lymph nodes, blood, spleen, organs), how many of them there are, and how aggressively they behave under the microscope and on molecular testing. For acute leukemias the more useful question is often “what is the risk category” rather than “what is the stage,” because cytogenetic and molecular markers predict outcome more reliably than anatomy. The staging or risk system in use is therefore disease specific, and the diagnostic report from leading cancer centres in the region or any other NCR centre will name the exact framework being used. (See the WHO 5th edition classification of haematolymphoid tumours.)
Why Blood Cancers Are Not Staged Like Solid Tumours
Leukemia begins in blood-forming stem cells of the bone marrow and almost always involves the entire marrow space and the peripheral blood at diagnosis. There is no localised “stage 1” the way a small breast lump is stage 1, because by the time the disease is detectable it is already systemic. Lymphoma can be localised to a single lymph node region in some cases, so it does use an anatomic stage, but the stage is anchored to which side of the diaphragm the nodes sit on, not to tumour size. Multiple myeloma involves plasma cells distributed throughout the bone marrow, so its staging system is built from blood biomarkers (albumin, beta-2 microglobulin, lactate dehydrogenase) and from cytogenetic risk markers, not from tumour bulk. The National Cancer Institute PDQ summaries describe these differences in detail.
Subtypes of Blood Cancer Covered on This Page
This guide covers the main blood cancers seen at NCR cancer centres. Among the leukemias these are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Among the lymphomas the page covers Hodgkin lymphoma (HL), and the non-Hodgkin lymphomas including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma and the T-cell lymphomas. Among plasma cell disorders the page covers multiple myeloma along with smouldering myeloma, MGUS and solitary plasmacytoma. Myeloproliferative neoplasms and the myelodysplastic syndromes sit on the border of blood cancer and are mentioned briefly because the same hematology teams across Delhi, Gurgaon and Noida manage them.
Acute Lymphoblastic Leukemia: Risk Stratification
Adult ALL is not staged by anatomy. Risk groups are defined by age at presentation, white cell count at diagnosis, immunophenotype (B-lineage versus T-lineage versus mature B-cell), cytogenetics and the response to induction chemotherapy measured as measurable residual disease (MRD) at end of induction and end of consolidation. Philadelphia chromosome positive disease (the BCR-ABL1 fusion from t(9;22)), KMT2A rearrangements, hypodiploidy and complex karyotype place a patient in the high risk group. Pediatric ALL uses the National Cancer Institute Rome criteria, which split children into standard and high risk on the basis of age and white cell count, with protocol specific further refinement on the basis of cytogenetics and early treatment response. The ESMO Clinical Practice Guidelines for adult ALL describe the current risk framework.
Acute Myeloid Leukemia: ELN 2022 Risk Categories
AML uses the European LeukemiaNet 2022 risk categorisation, which sorts patients into favorable, intermediate and adverse risk on the basis of cytogenetics and molecular markers. Favorable risk includes the core binding factor leukemias (t(8;21) and inv(16)) and AML with mutated NPM1 in the absence of a high allelic ratio FLT3-ITD. Adverse risk includes complex karyotype, monosomal karyotype, TP53 mutation, the secondary AML mutation panel (ASXL1, RUNX1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2) and FLT3-ITD with high allelic ratio in the absence of NPM1 mutation. Acute promyelocytic leukemia (APL), driven by the t(15;17) PML-RARA fusion, is treated as its own category because it has its own (largely chemotherapy free) treatment paradigm. The full criteria are published in the Döhner et al. 2022 ELN recommendations in Blood.
Chronic Myeloid Leukemia: Chronic, Accelerated and Blast Phase
CML is “staged” as chronic phase, accelerated phase or blast phase using the European LeukemiaNet criteria. Most patients in NCR are diagnosed in chronic phase, often as an incidental finding on a routine complete blood count done before surgery or for an insurance medical, where a very high white cell count and a basophilia on the smear are the only clue. Once treatment begins with a tyrosine kinase inhibitor, the more important number is the BCR-ABL1 transcript level on quantitative PCR, measured at three, six and twelve months and tracked on the international scale. Failure to reach defined molecular milestones triggers a switch in tyrosine kinase inhibitor or a search for kinase domain mutations. The Hochhaus et al. 2020 ELN CML recommendations are the reference standard.
Chronic Lymphocytic Leukemia: Rai and Binet Staging
CLL has two clinical staging systems in use. The Rai system, used more often in North America, runs from stage 0 (lymphocytosis only) through stage IV (lymphocytosis with thrombocytopenia) and is based on physical examination and blood counts. The Binet system, used more often in Europe and at most Indian centres, uses stages A, B and C on the basis of the number of involved lymph node areas and the presence of anemia or thrombocytopenia. Modern practice adds the CLL International Prognostic Index, which combines TP53 status, IGHV mutation status, beta-2 microglobulin, clinical stage and age into a single risk score. The ESMO CLL guidelines are the reference for current practice.
Hodgkin Lymphoma: Lugano Classification
Hodgkin lymphoma is staged using the Lugano classification, which is an update of the older Ann Arbor system. Stage I disease involves a single lymph node region, stage II involves two or more regions on the same side of the diaphragm, stage III involves regions on both sides of the diaphragm, and stage IV involves diffuse extralymphatic organ involvement. Each stage carries an A or B suffix depending on the absence or presence of systemic “B symptoms” (fever, drenching night sweats and significant weight loss). Bulky disease (a nodal mass larger than ten centimetres or greater than one third of the chest diameter) is also recorded because it influences treatment intensity. PET-CT response on the Deauville five-point scale at interim and end-of-treatment scans now drives response-adapted therapy decisions. The Cheson et al. Lugano classification paper is the primary reference.
Non-Hodgkin Lymphoma Stage and IPI Scores
Non-Hodgkin lymphomas use the same Lugano stage from I to IV, but anatomic stage on its own is not enough to predict outcome for diffuse large B-cell lymphoma (DLBCL), the commonest aggressive lymphoma. The International Prognostic Index (IPI) adds age over sixty, raised lactate dehydrogenase, ECOG performance status of two or more, stage III or IV, and more than one extranodal site, with each factor scoring one point. Follicular lymphoma uses the FLIPI and FLIPI-2 scores. Mantle cell lymphoma uses the MIPI score. Burkitt lymphoma is treated as a high risk disease at any stage because of its very rapid doubling time. The ESMO DLBCL guidelines describe how stage and IPI together drive treatment intensity.
Multiple Myeloma: Revised International Staging System
Multiple myeloma is staged using the Revised International Staging System (R-ISS), which combines serum albumin, beta-2 microglobulin, lactate dehydrogenase and high risk cytogenetics by FISH (del(17p), t(4;14), t(14;16)) into stages I, II and III. The newer R2-ISS, published in 2022, adds 1q gain or amplification as an additional adverse marker. Diagnosis itself uses the International Myeloma Working Group criteria, which require a clonal plasma cell population in the marrow at ten percent or more (or a biopsy proven plasmacytoma) plus one or more myeloma defining events such as hypercalcemia, renal insufficiency, anemia or lytic bone lesions. The IMWG updated criteria are the international standard.
Symptoms of Acute Leukemia
Acute leukemias usually arrive over the course of weeks. Patients describe a sudden tiredness that does not improve with rest, fevers without an obvious source of infection, bruises that appear from nothing, gum bleeding while brushing, repeated nose bleeds, pinpoint red spots on the legs, breathlessness while climbing one flight of stairs, and pain in the long bones of the legs or in the breastbone. Children with acute leukemia often present with limp, refusal to walk, or persistent low grade fever that the family pediatrician has been treating as a viral illness. Any patient walking into an OPD at leading cancer centres in the region or a a leading cancer centre or a leading cancer centre with this combination of complaints will receive an urgent complete blood count and peripheral smear, and an abnormal smear triggers a same day or next day bone marrow procedure.
Symptoms of Chronic Leukemia
Chronic leukemias creep in. CML is often picked up on a routine blood test done before surgery or for an insurance medical, where a very high white cell count is the only clue. CLL is frequently spotted because a lymph node in the neck or armpit has been slowly enlarging for months without pain, or because a routine blood test ordered for some unrelated reason returns with an unexplained lymphocytosis. Constitutional symptoms (fatigue, low grade fevers, night sweats, weight loss) are common in advanced chronic leukemia but unusual at first diagnosis, which is why so many patients in NCR are diagnosed during a check up rather than from a complaint that took them to a doctor.
Symptoms of Lymphoma
Lymphomas tend to announce themselves as a painless rubbery lump in the neck, armpit or groin that does not go away after a course of antibiotics. Hodgkin lymphoma in young adults sometimes brings drenching night sweats that soak the bedsheet, fevers that rise and fall in cycles (the classical Pel-Ebstein pattern), weight loss of more than ten percent of body weight in six months, and itching all over the body without a rash. Mediastinal lymphomas can cause a dry cough, swelling of the face in the morning, and a feeling of fullness in the chest, sometimes with superior vena cava obstruction in advanced cases. Extranodal lymphomas of the stomach, small bowel, skin, brain or testis present with symptoms specific to those organs and are frequently mistaken for tuberculosis or for benign lumps before a biopsy is finally taken.
Symptoms of Multiple Myeloma
Multiple myeloma usually presents with bone pain in the back or ribs that is worse on movement, height loss because of vertebral collapse, kidney problems found on a routine creatinine test, anemia that does not respond to iron therapy, repeated chest or urinary infections, and high calcium levels causing constipation, confusion or excessive thirst. The classic mnemonic is CRAB: hypercalcemia, renal failure, anemia and bone lesions. A meaningful share of myeloma diagnoses in NCR are made when a patient has been treated for “spondylitis” or “lumbar spondylosis” for several months before an X-ray reveals lytic bone lesions and a serum protein electrophoresis confirms a monoclonal band.
Causes and Risk Factors for Blood Cancer
For most blood cancers a single cause cannot be identified in any one patient. The biology involves random mutations in the DNA of a stem cell in the bone marrow or in a lymphocyte in a lymph node, which then expands as a clone. Recognised and suspected risk factors include prior exposure to high dose ionising radiation, prior chemotherapy with alkylating agents or topoisomerase II inhibitors for an earlier cancer, occupational exposure to benzene in petroleum, paint and rubber industries, smoking for AML and some lymphomas, certain pesticide exposures in agricultural workers, infection with Epstein-Barr virus (Burkitt and some Hodgkin lymphomas), human T-cell leukemia virus type 1, hepatitis C virus (some B-cell lymphomas), HIV related immunosuppression, post transplant immunosuppression, autoimmune diseases such as Sjögren syndrome and rheumatoid arthritis, and inherited conditions such as Down syndrome, Fanconi anemia, ataxia telangiectasia and Li-Fraumeni syndrome. Family history of a hematologic cancer modestly raises risk for first degree relatives but most patients have no affected family member. The IARC Monographs on carcinogenic hazards set out the evidence for the chemical and radiation exposures.
Diagnosis: Blood Counts, Smear and Bone Marrow
The starting point for any suspected blood cancer in Delhi, Gurgaon or Noida is a complete blood count with a peripheral smear reviewed by a hematopathologist. Abnormal counts, blast cells on the smear, or unexplained cytopenias trigger a bone marrow aspiration and trephine biopsy from the posterior iliac crest, usually done under local anesthesia in an outpatient procedure room at leading cancer centres in the region Memorial, a leading cancer centre Saket, a leading cancer centre Indraprastha or a leading cancer centre. The marrow sample is then sent for morphology, flow cytometry immunophenotyping, conventional karyotyping, fluorescence in situ hybridization for disease specific probes, and reverse transcription PCR or next generation sequencing for targetable fusions and mutations. Cerebrospinal fluid examination by lumbar puncture is mandatory at diagnosis for ALL and for high risk AML to rule out central nervous system involvement.
Flow Cytometry, Cytogenetics and Molecular Tests in Leukemia
For acute leukemias the standard workup follows the WHO 2022 classification and includes flow markers for lineage assignment (CD19, CD10, CD20, CD22 and TdT for B-ALL; CD3, CD5, CD7 for T-ALL; CD13, CD33, CD117, MPO for AML), cytogenetics for translocations such as t(9;22) BCR-ABL1, t(15;17) PML-RARA, t(8;21) RUNX1-RUNX1T1, inv(16) CBFB-MYH11 and KMT2A rearrangements, and a molecular panel for FLT3-ITD, FLT3-TKD, NPM1, CEBPA, IDH1, IDH2, TP53 and measurable residual disease assays. For CML, diagnosis is confirmed by detection of the BCR-ABL1 transcript on quantitative PCR from peripheral blood, with the baseline transcript level reported on the international scale. For CLL, peripheral blood flow cytometry showing a clonal CD5 positive, CD23 positive, CD19 positive B-cell population with kappa or lambda light chain restriction is sufficient, supplemented by FISH for del(17p), del(11q), trisomy 12 and del(13q), and TP53 sequencing. The International Consensus Classification of myeloid neoplasms sets out the current diagnostic criteria.
Diagnosis of Lymphoma: Excisional Biopsy and PET-CT
For lymphomas the diagnostic standard is an excisional lymph node biopsy rather than a fine needle aspirate, sent for hematoxylin and eosin staining, immunohistochemistry (CD20, CD3, CD5, CD10, BCL2, BCL6, MYC, CD30, CD15, EBER, Ki-67 and disease specific markers), and where indicated FISH for MYC, BCL2 and BCL6 rearrangements to identify double-hit and triple-hit large B-cell lymphomas. Whole body fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET-CT) is the staging investigation of choice for FDG-avid lymphomas, replacing older bone marrow biopsies for Hodgkin and most diffuse large B-cell lymphomas where the PET is negative in the marrow. PET-CT is widely available across NCR private hospitals and at a tertiary cancer centre at subsidised rates.
Diagnosis of Multiple Myeloma: IMWG Criteria
For multiple myeloma the diagnostic criteria are those of the International Myeloma Working Group and require demonstration of a clonal plasma cell population in marrow at ten percent or more (or a biopsy proven plasmacytoma) plus one or more myeloma defining events: hypercalcemia, renal insufficiency, anemia, lytic bone lesions on whole body low dose CT or PET-CT, marrow plasma cell percentage of sixty or more, an involved to uninvolved free light chain ratio of one hundred or more, or more than one focal lesion on whole body MRI. Serum and urine protein electrophoresis with immunofixation, the serum free light chain assay, beta-2 microglobulin, albumin and lactate dehydrogenase complete the baseline workup. Whole body MRI or low dose CT has now replaced the older skeletal survey at most NCR tertiary centres because they pick up bone lesions earlier.
Treatment of Acute Lymphoblastic Leukemia
Treatment of ALL in adults uses pediatric inspired multi-agent chemotherapy regimens such as GMALL, BFM and CALGB 10403 in younger adults, and lower intensity protocols in older patients, with the addition of a BCR-ABL1 tyrosine kinase inhibitor (imatinib, dasatinib or ponatinib) for Philadelphia chromosome positive disease. Blinatumomab, a CD19 directed bispecific T-cell engager, is now standard for measurable residual disease positive B-ALL after induction based on the BLAST and TOWER trials, and inotuzumab ozogamicin, a CD22 directed antibody drug conjugate, is used in relapsed disease based on INO-VATE ALL. Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy approved on the basis of the ELIANA trial, is available for pediatric and young adult relapsed or refractory B-ALL. Indigenous CAR-T programs at a tertiary cancer centre and a tertiary cancer centre (NexCAR19, the IIT Bombay and a tertiary cancer centre partnership product) have begun offering this therapy in India at a fraction of the global cost. Allogeneic stem cell transplant in first remission is reserved for high risk patients.
Treatment of Acute Myeloid Leukemia
Treatment of AML in fit younger adults uses 7+3 induction with cytarabine and an anthracycline, followed by risk adapted consolidation with high dose cytarabine for favorable risk and allogeneic transplant for intermediate and adverse risk. Midostaurin is added for FLT3 mutated AML based on the RATIFY trial, gemtuzumab ozogamicin for CD33 positive favorable and intermediate risk AML based on ALFA-0701, and CPX-351 (liposomal cytarabine and daunorubicin) for therapy related and AML with myelodysplasia related changes based on the Lancet 301 trial. In older or unfit patients the standard of care is now venetoclax combined with azacitidine based on the VIALE-A trial, or venetoclax with low dose cytarabine based on VIALE-C. Targeted agents include ivosidenib for IDH1 mutated disease, enasidenib for IDH2 mutated disease and gilteritinib for relapsed FLT3 mutated AML based on ADMIRAL. Acute promyelocytic leukemia is treated with all-trans retinoic acid and arsenic trioxide based on APL0406, achieving cure rates above ninety percent without conventional chemotherapy in standard risk disease.
Treatment of Chronic Myeloid Leukemia
Treatment of CML is built around BCR-ABL1 tyrosine kinase inhibitors. First line options include imatinib, nilotinib, dasatinib and bosutinib. Second and third line options include ponatinib for T315I mutated disease and asciminib, the first STAMP inhibitor, approved on the basis of the ASCEMBL trial. Treatment free remission is now an accepted goal in selected patients who achieve and maintain a deep molecular response, supported by the STIM, EURO-SKI and DASFREE trials. In Delhi, Gurgaon and Noida, generic imatinib is widely available and has changed CML from a fatal disease into a chronic condition with near normal life expectancy. The a leading cancer centre Foundation Glivec International Patient Assistance Programme provides free innovator imatinib to eligible patients registered through partner hospitals including a tertiary cancer centre and a tertiary cancer centre.
Treatment of Chronic Lymphocytic Leukemia
Treatment of CLL has shifted decisively from chemoimmunotherapy to targeted therapy. Bruton tyrosine kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and the BCL2 inhibitor venetoclax combined with the anti-CD20 antibody obinutuzumab are now standard first line options, supported by the RESONATE-2, ELEVATE-TN, SEQUOIA, CLL14 and MURANO trials. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) remains an option for younger fit patients with mutated IGHV and no TP53 abnormality. Pirtobrutinib, a non-covalent BTK inhibitor, is approved for patients who have progressed on covalent BTK inhibitors based on the BRUIN trial. The choice between continuous BTK inhibitor therapy and a fixed duration venetoclax based regimen is one of the more common decision points discussed in NCR hematology clinics.
Treatment of Hodgkin and Non-Hodgkin Lymphoma
Hodgkin lymphoma is treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for early and advanced stage disease, with escalated BEACOPP reserved for selected high risk advanced cases. Brentuximab vedotin, a CD30 directed antibody drug conjugate, combined with AVD has become a new standard for advanced stage classical Hodgkin lymphoma based on the ECHELON-1 trial. Checkpoint inhibitors nivolumab and pembrolizumab are approved for relapsed and refractory disease based on CheckMate 205 and KEYNOTE-204. Diffuse large B-cell lymphoma is treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) for six cycles, with polatuzumab vedotin substituted for vincristine in the Pola-R-CHP regimen for intermediate and high risk disease based on the POLARIX trial. Relapsed and refractory DLBCL is treated with second line chemoimmunotherapy followed by autologous transplant in chemosensitive patients, or with CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) based on ZUMA-1, JULIET, TRANSCEND, ZUMA-7, BELINDA and TRANSFORM. Bispecific antibodies epcoritamab and glofitamab are emerging options. Follicular and mantle cell lymphomas have their own dedicated regimens, with brexucabtagene autoleucel CAR-T approved for relapsed mantle cell lymphoma on the basis of ZUMA-2.
Treatment of Multiple Myeloma
Treatment of multiple myeloma in transplant eligible patients begins with quadruplet induction using daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-VRd) based on the GRIFFIN and PERSEUS trials, followed by autologous stem cell transplant, consolidation and lenalidomide maintenance. Transplant ineligible patients receive Dara-VRd or Dara-Rd based on MAIA. Relapsed disease has many options including carfilzomib, pomalidomide, isatuximab, elotuzumab, selinexor, belantamab mafodotin and the new T-cell engaging therapies. CAR-T therapies idecabtagene vicleucel and ciltacabtagene autoleucel are approved on the basis of KarMMa and CARTITUDE-1, with CARTITUDE-4 supporting earlier use. Bispecific antibodies teclistamab, elranatamab and talquetamab target BCMA and GPRC5D and offer off the shelf alternatives to CAR-T. The EHA-ESMO myeloma guidelines describe how these options are sequenced.
Allogeneic Stem Cell Transplant in NCR
Allogeneic stem cell transplantation remains the only curative option for many high risk acute leukemias, for some high risk myelodysplastic syndromes and for certain relapsed lymphomas. It is offered at a tertiary cancer centre Delhi, a tertiary cancer centre Rohini, a leading cancer centre, a leading cancer centre Memorial Gurgaon, a leading cancer centre Indraprastha, a leading cancer centre Gurgaon and a leading cancer centre Gurgaon, with both matched sibling donor and haploidentical donor programmes available. Donor search through the DKMS-BMST registry and other Indian and international registries supplements family donor options when no sibling match is available. Supportive care including transfusion support, antifungal prophylaxis with posaconazole or isavuconazole, growth factors, central venous access and palliative care input from the start of treatment are integral to all blood cancer transplant programmes in NCR. Post transplant care including CMV monitoring, GVHD management and long term immunosuppression carries on for the first one to two years after transplant.
Cost of Blood Cancer Treatment in Delhi, Gurgaon and Noida
Cost of blood cancer treatment in Delhi-NCR varies widely by disease type, risk group, insurance coverage and whether care is delivered at a government centre, a trust hospital or a private tertiary hospital. Diagnostic workup for a new blood cancer including complete blood count, peripheral smear, bone marrow aspirate and biopsy, flow cytometry, conventional cytogenetics, FISH panel, targeted next generation sequencing, whole body PET-CT where indicated, HLA typing for transplant candidates and baseline cardiac, renal and infectious disease screening typically runs between eighty thousand and three lakh rupees in private hospitals. At a tertiary cancer centre, a tertiary cancer centre and other government centres the same workup is available at subsidised rates and is frequently covered in full for eligible patients under Ayushman Bharat PMJAY, CGHS and state schemes. AML 7+3 induction including a four to six week hospital stay costs between four and twelve lakh rupees in private NCR hospitals, with venetoclax-azacitidine for older patients adding a comparable amount per cycle. ALL induction and consolidation over two to three years ranges from six to twenty lakh rupees, with blinatumomab or inotuzumab adding eight to twenty five lakh rupees per course where indicated. Generic imatinib for CML costs between eight hundred and three thousand rupees a month and is available free under the a leading cancer centre Foundation programme for eligible patients. Ibrutinib for CLL costs around forty to seventy thousand rupees a month in generic form. Six cycles of ABVD for Hodgkin lymphoma cost between one and a half and four lakh rupees in private day care, and six cycles of R-CHOP for DLBCL cost between three and eight lakh rupees. Pola-R-CHP per POLARIX adds eight to fifteen lakh rupees. CAR-T cell therapy is the highest cost line item, ranging from forty to four hundred lakh rupees, with the indigenous NexCAR19 product substantially cheaper than imported options. Multiple myeloma induction with Dara-VRd costs between ten and thirty lakh rupees, with autologous transplant adding ten to twenty lakh rupees in private NCR hospitals. Allogeneic transplant ranges from fifteen to forty lakh rupees for matched sibling donor procedures and is higher for matched unrelated donor or haploidentical transplants. Financial assistance is available through Ayushman Bharat PMJAY for eligible families, the Prime Minister National Relief Fund, the Health Minister Cancer Patient Fund administered through a tertiary cancer centre and a tertiary cancer centre, CGHS, ESI, state schemes, Tata Trusts, the Indian Cancer Society, CanKids KidsCan for paediatric patients, Cuddles Foundation for nutrition support, a leading cancer centre Foundation for targeted therapy access and pharma company patient access programmes for innovator products. Detailed package rates are published by the National Health Authority Ayushman Bharat PMJAY oncology package, and audit data is available from the ICMR-NCDIR National Cancer Registry Programme.
Frequently Asked Questions
Is blood cancer curable? Many blood cancers are curable or achieve long durable remission with modern treatment. Acute lymphoblastic leukemia in children has cure rates above eighty percent, chronic myeloid leukemia on tyrosine kinase inhibitors has near normal life expectancy, Hodgkin lymphoma has cure rates above eighty percent for early stage and around seventy percent for advanced stage, and diffuse large B-cell lymphoma is cured in around sixty to seventy percent of cases with R-CHOP or Pola-R-CHP. Multiple myeloma is treatable and remissions are durable but the disease is not generally considered curable.
What is the difference between leukemia, lymphoma and myeloma? Leukemia arises in blood forming cells of the bone marrow and spills into the peripheral blood, lymphoma arises in lymphocytes and grows in lymph nodes or extranodal lymphoid tissue, and myeloma arises in plasma cells in the bone marrow. The distinction matters because diagnostic workup and treatment differ significantly.
What are the first symptoms of blood cancer? Common early symptoms include unexplained fatigue, fever without obvious infection, drenching night sweats, unintentional weight loss, easy bruising or bleeding, pale skin, bone pain, persistent lymph node swelling and recurrent infections. Any of these symptoms lasting more than two weeks should prompt a complete blood count and clinical evaluation.
How is blood cancer diagnosed? Diagnosis begins with a complete blood count and peripheral smear, followed by bone marrow aspirate and biopsy with flow cytometry, cytogenetics, FISH and molecular testing for leukemia and myeloma, or lymph node biopsy with immunohistochemistry and molecular testing for lymphoma. Imaging with PET-CT is standard for lymphoma staging.
Does blood cancer run in families? Most blood cancers are sporadic but there are known inherited predisposition syndromes including germline RUNX1, CEBPA, DDX41, GATA2, ANKRD26 and ETV6 mutations, Li-Fraumeni syndrome, ataxia telangiectasia, Fanconi anaemia, Down syndrome and familial CLL. First degree relatives of CLL patients have a two to eight fold increased risk.
What is CAR-T cell therapy? Chimeric antigen receptor T cell therapy involves collecting the patient’s own T cells, genetically modifying them to express a receptor targeting a cancer antigen such as CD19 or BCMA, expanding them in a lab and infusing them back. CAR-T is approved for acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and multiple myeloma. An indigenous Indian product NexCAR19 is available at substantially lower cost than imported options.
Where should I seek treatment for blood cancer in Delhi, Gurgaon and Noida? Major blood cancer and stem cell transplant centres in NCR include a tertiary cancer centre Delhi, a tertiary cancer centre, a tertiary cancer centre and Research Centre Rohini, Dr BL Kapur a leading cancer centre, a leading cancer centre Gurgaon, a leading cancer centre The Medicity Gurgaon, a leading cancer centre Gurgaon, a leading cancer centre Indraprastha, a leading cancer centre Saket, Action Cancer Hospital and a leading cancer centre Noida. Choice of centre should consider disease type, transplant need, insurance coverage and access to patient assistance programmes. The a tertiary cancer centre Evidence Based Management of Cancers in India document and the a tertiary cancer centre Department of Medical Oncology and BMT Unit protocols are widely used reference standards across NCR practice. Additional reference frameworks include the SEER Cancer Stat Facts, the NCCN Clinical Practice Guidelines in Oncology, the National Cancer Institute patient information pages and the ICMR consensus document for haematolymphoid malignancies.
Overview
Treatment Options